Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fosun Antigen 24-valent pneumococcal polysaccharide conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Fosun Adgenvax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Fosun Antigen 24-valent pneumococcal polysaccharide conjugate vaccine is an investigational multivalent polysaccharide-conjugate vaccine being developed by Fosun Adgenvax (a subsidiary of Fosun Pharma) for the prevention of pneumococcal disease and pneumococcal infections. The vaccine contains pneumococcal capsular polysaccharide antigens from 24 distinct serotypes of *Streptococcus pneumoniae* (specifically serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F), each individually conjugated to a carrier protein to enhance immunogenicity. By presenting these conjugated antigens, the vaccine stimulates the humoral and cellular immune systems, inducing T-cell dependent immune responses and immunological memory against the targeted serotypes. It is currently in Phase 1 clinical development in China.
- Other names
- 24-valent pneumococcal conjugate vaccine24-valent pneumococcal polysaccharide conjugate vaccine24价肺炎球菌多糖结合疫苗复星安特金 24价肺炎球菌多糖结合疫苗复星安特金24价肺炎球菌多糖结合疫苗
02
Targets
BCR (B-cell receptor recognizing pneumococcal capsular polysaccharides)CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on Fosun Antigen 24-valent pneumococcal polysaccharide conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fosun Antigen 24-valent pneumococcal polysaccharide conjugate vaccine.